Screener
Janux Therapeutics JANX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Assets | June 30,2026 / (unaudited) | December 31,2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $27,768 | $52,334 |
| Accounts receivable, net | 149 | — |
| Short-term investments | 943,145 | 914,233 |
| Prepaid expenses and other current assets | 12,275 | 9,320 |
| Total current assets | 983,337 | 975,887 |
| Restricted cash | 816 | 816 |
| Property and equipment, net | 3,260 | 3,852 |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's short-term investments?
- Janux Therapeutics (JANX) reported short-term investments of $943.15M in Q2 2026.
- How has Janux Therapeutics's short-term investments changed year-over-year?
- Janux Therapeutics's short-term investments decreased by 0.0% year-over-year, from $943.57M to $943.15M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Janux Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude